Logan Coy Related postsA Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer After Prior ChemotherapySeptember 11, 2026An Open-Label, Phase 2b Global Multicenter Cohort Trial of Zipalertinib in Locally Advanced or Metastatic NSCLC with Exon 20 Insertion and Uncommon/Single or Compound EGFR MutationsSeptember 11, 2026A Protocol to Assess the Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Low-Dose Lenalidomide (STAR-LLD) for the Treatment of Multiple MyelomaSeptember 11, 2026 Next postA Phase 2, Open-Label Study of PCS6422 with Capecitabine in Patients with Advanced or Metastatic Breast Cancer